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The definition of diabetes control varies widely 
among specialists of the disease. Proponents of 
"good" control believe that the goals of appropriate 
therapy for diabetes should include an all-out effort 
to obtain levels of fasting and postprandial blood 
glucose as close to those in the non-diabetic as pos-
sible. Certainly, good control has been proven to 
accomplish the following : 
1. Prevention of ketoacidosis 
2. Prevention of severe hypoglycemia 
3. Decrease in perinatal mortality and morbid-
ity 
4. Promotion of normal growth and develop-
ment of the juvenile diabetic 
5. Prevention of, or inhibition of, infection 
The evidence that hyperglycemia is responsible 
for vascular complications, particularly micro-
vascular disease, and that good control will prevent 
or inhibit the rapidity of the development of this 
pathologic process, or even reverse it, is the basis of 
this presentation. · 
At the outset, however, it must be appreciated 
that retinopathy, nephropathy, neuropathy, and 
large vessel disease may be the presenting manifesta-
tions of diabetes, and that it is possible to have exten-
sive vascular complications in the presence of rela-
tively mild glucose intolerance. Furthermore, 20% of 
juvenile-onset type, ketosis-prone diabetics of more 
than 25-years duration with continuous hypergly-
cemia do not have clinically impressive retinopathy 
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or nephropathy. Also, it has been noted that large 
vessel disease or neuropathy is absent in 20% to 40% 
of insulin-dependent diabetics. 
The evidence for good control is largely based on 
the following observations: 
I. Clinical studies 
2. Animal studies 
3. Histologic and electron microscopic data 
4. Biochemical studies 
5. Altered coagulopathy, viscosity, and hypoxia 
Recent studies in well-controlled juvenile diabet-
ics indicate that serial biopsies of quadriceps muscle 
have demonstrated ''.thinning" of previously thick-
ened capillary basement membrane, in contrast to 
persistent and increasing thickening of capillary base-
ment membrane in poorly controlled diabetic pa-
tients. In addition , it has recently been demonstrated 
that diabetic vascular lesions developed in normal 
kidneys transplanted into patients with diabetes mel-
litus after a period of two years, while transplanted 
kidneys in non-diabetic control patients of the same 
age and type remained unaffected; this also gives 
great support to the concept of good control. 
Animal studies with diabetic Chinese hamsters, 
mice, rats, dogs, and monkeys have indicated that 
good control with insulin therapy or islet trans-
plantation prevents or reverses lesions in the eyes, 
kidneys, or nerves. 
Histologic and electron microscopic studies of 
capillary basement membrane of muscle have given 
conflicting results. One group of observers indicates 
that basement thickening is already genetically pre-
determined, while other investigators relate capillary 
basement membrane thickening to the duration of 
diabetes. Methodology of technique, the patient' s 
age, unknown duration of existing diabetes, and cri-
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teria for the diagnosis of diabetes have to be clarified 
before coming to definitive conclusions. 
Biochemical studies indicate that hyperglycemia 
or insulin deficiency produces alteration in vascular 
basement membrane composition, as well as accumu-
lation of glucose-derived substances, such as sorbitol 
in the lens of the eye, Schwann' s cell, and aorta. 
Recently, an elevation of glycolysated hemoglobin 
(HbAJc) has been noted in the blood of diabetic mice 
as well as human diabetics . The glycolysation of he-
moglobin appears to be a post-synthetic modification 
of HbA which is dependent on the degree and dura-
tion of hyperglycemia. 
Recent data reveal that platelet aggregation is 
more intense in diabetic patients, with increased sen-
sitivity of platelets to aggregation from adenosine 
diphosphate (ADP) and epinephrine. This sensitivity 
correlates with elevated levels of Von Willebrand fac-
tor, which in turn appears to be influenced by growth 
hormone. Also, platelets from diabetic subjects are 
more sensitive to arachidonic acid-induced aggrega-
tion, which can be abolished by aspirin, which is a 
prostoglandin synthetase-inhibitor. 
Spontaneous fibrinolytic activity of the blood is 
abnormally low in persons with diabetes mellitus, 
and implies a poor defense mechanism against fibrin 
deposits in the vessel walls, which conceivably may 
contribute to the development of diabetic micro-
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angiopathy. Increased red blood cell aggregation and 
alterations in plasma protein changes in diabetics, 
with their effects on blood viscosity and flow , may 
also play a role in accelerating the rate of progression 
of diabetic microangiopathy . 
In addition, the decreased reactivity of HbAlc 
with 2,3 diphosphoglycerate might impair oxygen un-
loading in diabetes, and contribute to tissue hypoxia, 
which may have pathogenetic implications in the de-
velopment of diabetic angiopathy. 
Whether reversal of hyperglycemia, as well as 
the use of agents to inhibit some of the above-de-
scribed adverse effects of the diabetic milieu, may 
affect the development of diabetic microangiopathy is 
far from settled. Consideration must be given to more 
intense regulation of dietary factors; use of the newer 
oral hypoglycemic agents; administration of insulin 
three or four times daily for better control; long-term 
studies on the use of aspirin, and other platelet-aggre-
gating inhibitors, as well as phosphate supplements; 
availability and effectiveness of growth hormone in-
hibiting agents; the use of substances which can inter-
fere with the post-ribosomal steps of basement mem-
brane assembly; and finally , improvements in the 
delivery of insulin, whether it be by better biome-
chanical engineering or by increased knowledge of 
immunologic and other biologic defenses in the use of 
islet or organ transplantation. 
